Senior Oncology Field Manager—Desmoid Tumor Launch

Immunome; United States; Remote; USD 210,000 - 235,000; Full time

Benefits offered by this job

Medical, dental, and vision insurance

401(k) with employer match

Life insurance & disability

Paid time off & holidays

Parental leave

Job summary

Immunome is seeking a Senior Oncology Account Manager to drive territory-level sales for varegacestat in desmoid tumors, building relationships with healthcare providers and executing local brand strategy.

You will partner with Market Development, Marketing, Market Access, and Medical Affairs to deliver compliant, insight-driven customer experiences, aiming to establish Immunome as a trusted partner in the desmoid tumor community. Expect 60–80% travel and a dynamic, patient-centric culture.

Qualifications

• Bachelor's degree required.
• 7+ years in pharma/biotech oncology sales.
• Oncology launch experience is highly desirable.
• Oral oncolytic experience is highly desirable.
• Proven track record of meeting or exceeding sales targets.
• Willingness to travel up to 60–80%.

Responsibilities

• Achieve or exceed territory sales goals for varegacestat.
• Develop territory business plans with target accounts.
• Deliver compliant, value-based messages to providers.
• Maintain understanding of desmoid tumor landscape and payer dynamics.
• Report territory activity and results using CRM tools.
• Engage physicians, nurses, and staff; build KOL relationships.

Skills

Relationship building

Communication

Oncology sales

CRM proficiency

Territory management

Travel

Education

Bachelor's degree

Tools

CRM systems

Job description

Immunome is seeking a Senior Oncology Account Manager to drive territory-level sales for varegacestat in desmoid tumors, building relationships with healthcare providers and executing local brand strategy.

You will partner with Market Development, Marketing, Market Access, and Medical Affairs to deliver compliant, insight-driven customer experiences, aiming to establish Immunome as a trusted partner in the desmoid tumor community. Expect 60–80% travel and a dynamic, patient-centric culture.